Investment Rating - The report maintains an "Accumulate" rating for the industry, indicating a forecasted increase of over 10% relative to the benchmark index in the next 6 to 12 months [27]. Core Insights - The overall market performance of the Beijing Stock Exchange (BSE) shows a decline, with the BSE 50 index dropping by 3.59% to close at 1531.55 points as of January 30, 2026. In comparison, the Shanghai and Shenzhen indices showed minor fluctuations [4][10]. - The average market capitalization of the 292 constituent stocks on the BSE is 3.207 billion yuan, with a total industry market value of 936.302 billion yuan and a circulating market value of 580.261 billion yuan [4][10]. - The report highlights the top-performing sectors for the week, including Oil and Petrochemicals (33.99%), Media (4.97%), Agriculture, Forestry, Animal Husbandry, and Fishery (4.69%), Transportation (2.28%), and Communications (2%) [4][17]. Summary by Sections BSE Market Overview - As of January 30, 2026, the BSE has 292 constituent stocks, with an average market capitalization of 3.207 billion yuan. The BSE 50 index experienced a decline of 3.59% during the week, while the Shanghai Composite Index and other indices showed minimal changes [4][10]. - The average daily trading volume for the BSE was 28.731 billion yuan, reflecting a 7.20% increase from the previous week, with a turnover rate of 5.88% [15]. New Stocks on BSE - One new stock, Meidele (920119.BJ), was issued during the week. Additionally, several companies are at various stages of the IPO process, including Huadian Guangda, which has been accepted for review [5][22]. Key News from BSE - The BSE released a revised guideline for sustainable development reporting on January 30, 2026, aimed at enhancing the quality of information disclosure among listed companies. This includes new application guidelines focusing on pollutant emissions, energy use, and water resource utilization [6][24]. - The first IPO of the year was accepted for Beijing Huadian Guangda Environmental Co., which specializes in new catalytic materials for air pollution control, aiming to raise approximately 260 million yuan [6][24]. Investment Strategy - The report suggests focusing on sectors expected to perform well in 2026, including Data Centers, Robotics, Semiconductors, Consumer Goods, and Military Information Technology. Specific companies highlighted include KLT, Suzhou Axis, and Hualing Co. [25].

Investment Rating - The industry investment rating is maintained at "Overweight" [1][27]. Core Insights - The report highlights that the overall performance of the Beijing Stock Exchange (BSE) is expected to show significant results in 2026, with a focus on high-quality development and investment opportunities in various sectors [6][25]. Summary by Sections BSE Market Overview - As of January 30, 2026, the BSE has 292 constituent stocks with an average market capitalization of 3.207 billion [4][10]. - The BSE 50 Index experienced a decline of 3.59%, closing at 1531.55 points, while the Shanghai and Shenzhen indices showed minor fluctuations [4][10]. - The average daily trading volume for the week was 28.731 billion, an increase of 7.20% from the previous week, with a turnover rate of 5.88% [4][15]. Sector Performance - The top five performing sectors on the BSE for the week were: - Oil and Petrochemicals: 33.99% - Media: 4.97% - Agriculture, Forestry, Animal Husbandry, and Fishery: 4.69% - Transportation: 2.28% - Communication: 2% [4][17]. New Stocks - One new stock was issued during the week, Meidel (920119.BJ), with updates on the status of other companies in the review process [5][22]. Key News - The BSE released a revised "Guidelines for the Preparation of Sustainable Development Reports" to enhance the quality of sustainability disclosures among listed companies [6][24]. - The first IPO of the year was accepted, with Beijing Huadian Guangda Environment Co., Ltd. aiming to raise approximately 260 million by issuing up to 32.2 million shares [6][24]. Investment Strategy - The report suggests focusing on the following sectors for investment in 2026: 1. Data Centers: KLT and Shuguang Data Creation 2. Robotics: Suzhou Axis, Audiwei, JunChuang Technology, and Fuheng New Materials 3. Semiconductors: Hualing Co. and Kaide Quartz 4. Consumer Goods: Taihu Snow, Boshenglong, Lusi Co., Kangbiter, and Thunder God Technology 5. Military Information Technology: Chengdian Guangxin and Xingtuzhihui [6][25].

详解 2025 年理财年度报告： 规模稳步增长，增配现金类资产 评级： 增持（维持） 分析师：戴志锋 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 分析师：邓美君 执业证书编号：S0740519050002 Email：dengmj@zts.com.cn 分析师：陈程 执业证书编号：S0740525110001 Email：chencheng07@zts.com.cn 基本状况 上市公司数 42 行业总市值(亿元) 146,116.35 行业流通市值(亿元) 139,898.72 报告摘要 相关报告 业绩增速有望稳中向好，资产质量持 续优化》2026-02-08 贷款 5.1-5.25 万亿元，社融增速为 8.3%》2026-02-07 门 红 奠 定 全 年 业 绩 稳 健 基 调 》 2026-01-31 银行 证券研究报告/行业点评报告 2026 年 02 月 09 日 风险提示事件：经济下滑超预期，经济恢复不及预期，数据更新不及时。 请务必阅读正文之后的重要声明部分 理财产品存续规模为 33.29 万亿元，同比增长 11.2%，全年合计增量为 3.34 万亿 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

1. Report Industry Investment Rating - The industry rating is "Overweight", expecting a gain of more than 10% relative to the benchmark index in the next 6 - 12 months [35] 2. Core Viewpoints - Since the New Year's Day, the A-share market has been experiencing the overlapping resonance of three factors: further changes in liability behavior, multi-directional catalysis on the asset side, and the transfer of the bond market's "good start" seasonal market to the equity market [2][8][9] - The bull market's confidence stems from the concentrated maturity of time deposits and the activation of deposits. From "current deposits - wealth management products - dividend - insurance policies - public funds", the attractiveness and the degree of embracing equity assets increase significantly [2] - Dividend - insurance policies can serve as an alternative to high - interest time deposits after maturity. The current time deposit interest rate is lower than the "guaranteed return" part of dividend - insurance policies [2][18] - With the rapid expansion of wealth management scale, relying solely on bond funds is difficult to meet the performance requirements, forcing funds to seek elasticity in equity assets. The structure of wealth management products is moving towards equity - linked ones [2][22] - The seasonality of the bond market has not disappeared but has shifted to the stock market, forming the "good start" of the stock market [2][25] - Forget the "expectation gap", and the flywheel effect of "money - production capacity" is emerging. AI can boost the reinvestment expectations of traditional industries, and the reinflation of products will lead to changes in capital expenditure and production capacity expansion [2] 3. Summary by Relevant Catalog 3.1 Understanding from the Liability - side Perspective - **Deposit Activation and Reinvestment**: Since 2022, time deposit interest rates have been lowered multiple times. The 1 - year deposit rate has dropped from 1.75% to 0.95%, and the 3 - year rate from 2.75% to 1.25%. The re - investment of time deposits shows a "trickle - down effect", with funds flowing to current deposits and equity - linked products. The attractiveness and the degree of embracing equity assets increase step - by - step from "current deposits - wealth management products - dividend - insurance policies - public funds" [11][14][17] - **Dividend - insurance Policies as an Alternative**: Dividend - insurance policies have a "guaranteed return + floating dividend" feature, with a guaranteed return capped at 1.75% and at least 70% of distributable surplus distributed to policyholders. They have higher investment returns, lower rigid costs for insurance companies, and relatively shorter effective durations. Their liability - side characteristics lead to a higher proportion of equity investment and shorter - term fixed - income investment [18][19] - **Equity - linked Fixed - income Products**: The rapid expansion of wealth management scale poses challenges to asset - side returns. Even with an optimistic assumption for the 2026 bond market, the upper limit of the return from bond funds is only 2.1%, so adding equity is needed to increase returns. Equity - linked fixed - income products are shifting from high - dividend to high - volatility and technology sectors [22] - **Impact on Stock - Bond Balance**: The seasonality of the bond market is caused by the maturity of various deposits and the behavior of banks to meet quotas. Due to the strong trend of deposit migration to wealth management and insurance, the funds that should have flowed into bonds have instead entered equity - linked wealth management products or dividend - insurance policies, leading to the transfer of the bond market's seasonality to the stock market [25] - **The Emergence of the Flywheel Effect**: The "expectation gap" thinking is suitable for a static environment of stock - fund games. Currently, at the moment of rapid switching of liability behavior, the institutions where liabilities flow first are more leading. The AI sector has a flywheel effect on traditional industries' reinvestment and employment, and the reinflation of products will drive capital expenditure and production capacity expansion in relevant industries [27][28][31]

【中泰研究丨晨会聚焦】固收吕品：多空互加筹码，债市迎来 "验牌时刻" 证券研究报告/晨会聚焦 2026 年 02 月 09 日 分析师：戴志锋 2、《【中泰研究丨晨会聚焦】医药祝嘉 琦：战略重视原料药板块，价格修复 +新业务增量；积极把握医药底部机 会》2026-02-04 3、《【中泰研究丨晨会聚焦】军工陈鼎 如：Space X 再申请百万颗卫星，商 业航天关注度持续提升》2026-02-03 今日预览 今日重点>> 【固收】吕品：多空互加筹码，债市迎来"验牌时刻" 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 欢迎关注中泰研究所订阅号 晨报内容回顾 1、《【中泰研究丨晨会聚焦】固收林 莎：如何在定位和投资上做好一只"固 收+"——基金四季报详细拆解》 2026-02-06 【食品饮料】何长天：快餐市场重焕生机，产品创新增时运营 研究分享>> 【固收】吕品：信用债类 ETF 持续净流出 请务必阅读正文之后的重要声明部分 今日重点 【固收】吕品：多空互加筹码，债市迎来"验牌时刻" 近两周以来，债市的行情不断修复。尤其是以二永、10 年内期限为代表的配置型品种来说，债 ...

Report Summary 1. Report Industry Investment Rating No industry investment rating information is provided in the report. 2. Core Viewpoints - Last week, the ChinaBond New Composite Index rose 0.08% throughout the week; short - term and medium - long - term pure bond funds rose 0.01% respectively; the CSI AAA Sci - tech Innovation Bond Index and the SSE Benchmark Market - making Corporate Bond Index rose 0.03% respectively [2]. - As of February 6, 2026, bond - type ETFs had a net outflow of 4.075 billion yuan in the past week, with interest - rate, credit, and convertible - bond ETFs having net inflows of 1.745 billion yuan, net outflows of 6.72 billion yuan, and net inflows of 0.9 billion yuan respectively [4]. - Overall, the net values of various types of bond ETF products generally rose last week. As of February 6, 2026, the 30 - year Treasury Bond ETF Boshi performed well, rising 0.74% for the week [5]. 3. Summary by Relevant Catalogs 3.1 Funds Flow - As of February 6, 2026, bond - type ETFs had a net outflow of 4.075 billion yuan in the past week. Interest - rate, credit, and convertible - bond ETFs had net inflows of 1.745 billion yuan, net outflows of 6.72 billion yuan, and net inflows of 0.9 billion yuan respectively. Among credit - type ETFs, short - term financing, corporate bonds, and urban investment bonds had net inflows of 3.274 billion yuan, 0.016 billion yuan, and 0.283 billion yuan respectively, while market - making credit bonds had a net outflow of 2.384 billion yuan, and sci - tech innovation bonds had a net outflow of 7.908 billion yuan. Since 2025, interest - rate, credit, and convertible - bond ETFs have had cumulative net inflows of 53.805 billion yuan, 459.605 billion yuan, and 33.807 billion yuan respectively, totaling 547.217 billion yuan [4]. 3.2 Net Value Performance - Overall, the net values of various types of bond ETF products generally rose last week. As of February 6, 2026, the 30 - year Treasury Bond ETF Boshi performed well, rising 0.74% for the week; the Treasury Bond ETF Huaxia rose 0.23%, and the Policy Financial Bond ETF rose 0.22%. The Convertible Bond ETF and the SSE Convertible Bond ETF fell 0.02% and 0.12% respectively last week [5]. 3.3 Performance of Credit Bond ETFs and Sci - tech Innovation Bond ETFs - As of February 6, 2026, the median unit net values of credit bond ETFs and sci - tech innovation bond ETFs were 1.0148 and 1.0026 respectively, rising 0.02% and 0.01% for the week. Among credit bond ETFs, the Credit Bond ETF Boshi performed relatively well, rising 0.03% for the week. Among sci - tech innovation bond ETFs, the Sci - tech Innovation Bond ETF Dacheng and the Sci - tech Innovation Bond ETF Yongying performed relatively well. As of February 6, 2026, the median discount rate of credit bond ETFs was 16BP, and that of sci - tech innovation bond ETFs was 17BP [6]. 3.4 Duration Tracking of Credit - type ETFs - As of February 6, 2026, the holding durations of short - term financing ETFs, corporate bond ETFs, and urban investment bond ETFs were 0.31 years, 1.90 years, and 2.08 years respectively. Among market - making credit bond ETFs, the median holding durations of products tracking the Shanghai Market - making Corporate Bond Index and the Shenzhen Market - making Corporate Bond Index were 3.57 years and 2.74 years respectively. Among sci - tech innovation bond ETFs, the median holding durations of products tracking the AAA Sci - tech Innovation Bond Index, the Shanghai AAA Sci - tech Innovation Bond Index, and the Shenzhen AAA Sci - tech Innovation Bond Index were 3.28 years, 3.18 years, and 3.14 years respectively [7].

Investment Rating - The report maintains an "Overweight" rating for the light industry manufacturing and textile apparel sectors [1]. Core Insights - Ralph Lauren's Q3 2026 performance exceeded expectations with a 12% year-on-year revenue increase and a 21.6% rise in net profit, driven by strong growth in China and a robust direct-to-consumer channel [5]. - The Milan Winter Olympics is expected to enhance the visibility and demand for sports brands, particularly benefiting companies like Li Ning and Anta, which have established partnerships for the event [6]. - The report highlights the resilience of the Chinese market and the ongoing premiumization of brands, indicating a shift from mass luxury to top-tier luxury business models [5][6]. Summary by Sections Company Performance - Ralph Lauren's revenue growth was over 30% in China, with North America and Europe also showing positive trends [5]. - Tapestry reported a 14% increase in net sales, with significant growth in its Coach brand [5]. Market Trends - The light industry manufacturing index rose by 0.96%, ranking 8th among 28 industries, while the textile apparel index increased by 1.32%, ranking 6th [11]. - The report notes a positive outlook for sports and outdoor products sales due to major sporting events in 2026, including the Winter Olympics and World Cup [6]. Sector Analysis - The report suggests focusing on companies with clear Olympic rights and product strategies, such as Anta and Li Ning, as they prepare for significant events [6]. - In the textile manufacturing sector, Uniqlo's FY26Q1 performance was above expectations, with a 20.3% increase in overseas markets [6]. Investment Recommendations - The report recommends monitoring companies like Bubble Mart for their ability to innovate and maintain market confidence through product launches and share buybacks [6]. - It also suggests looking into the AI eyewear market, highlighting the potential for growth as AI technology becomes more integrated into consumer products [6].

Investment Rating - The report maintains a "Buy" rating for key companies in the building materials sector, indicating an expected relative performance increase of over 15% in the next 6-12 months [6][110]. Core Insights - The building materials industry is at a turning point, with both demand and valuation expected to improve. The real estate sector is anticipated to stabilize, leading to a recovery in building materials demand. The report highlights that new construction starts in 2025 are projected to decline by 70% compared to 2021, with completions down by 40% and new home sales down by 50% [9][8]. - Rising prices of upstream raw materials such as asphalt, polypropylene, and polyethylene are expected to drive up building material prices, benefiting companies with pricing power [9][8]. - The report recommends several companies, including Beixin Building Materials, Oriental Yuhong, and Sanhe Tree, while suggesting to pay attention to companies like Rabbit Baby and China Liansu [9][8]. Summary by Sections Market Overview - The building materials sector is currently underweighted, with a configuration ratio of 0.72% as of Q4 2025, which is significantly lower than the historical average since 2010 [8]. - The cement and glass sectors are noted to be at low valuation levels, with the cement manufacturing PB at the 16th percentile and glass manufacturing PB also at the 16th percentile since 2010 [8]. Key Company Recommendations - Recommended companies include: - Beixin Building Materials: EPS forecasted to increase from 2.1 in 2024 to 3.5 in 2027, with a PE ratio decreasing from 13.4 to 8.2 [6]. - Conch Cement: EPS forecasted to rise from 1.5 in 2024 to 2.2 in 2027, with a PE ratio decreasing from 17.3 to 11.6 [6]. - China Jushi: EPS expected to grow from 0.6 in 2024 to 1.2 in 2027, with a PE ratio decreasing from 36.1 to 18.6 [6]. - Other companies include Weixing New Materials, Sanhe Tree, and Huaxin Cement, all rated as "Buy" or "Increase" [6]. Industry Trends - The report notes a significant increase in market share for consumer building materials over the past few years, with profitability in segments like waterproofing and piping at a low point, suggesting potential for recovery [9][8]. - The cement sector is expected to see a gradual recovery in profitability, with a current national cement market price decrease of 1% and a notable drop in average shipment rates [36][9]. - The float glass sector is experiencing a supply-side adjustment, with production capacity at a five-year low, indicating potential for price recovery [9][8]. Emerging Opportunities - The report highlights opportunities in overseas markets, particularly in Africa, Central Asia, and Southeast Asia, where rising populations and urbanization rates are creating demand for building materials [9][8]. - The electronic fabric market is also noted for its upward price trend due to supply constraints, with significant price increases observed in recent weeks [9][8]. Conclusion - The building materials industry is positioned for a recovery phase, driven by stabilization in the real estate market and rising raw material prices. The report emphasizes the importance of focusing on companies with strong pricing power and market positioning to capitalize on these trends [9][8].